|
|
   Sarilumab
|
|
|
| appearance as argument number 1 |
|
|
| (documentation Sarilumab EnglishLanguage "Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.[from Wikipedia]") | Medicine.kif 5262-5267 | |
| (subclass Sarilumab MonoclonalAntibody) | Medicine.kif 5260-5260 | Sarilumab 是 MonoclonalAntibody 的 subclass |
| appearance as argument number 2 |
|
|
| (diseaseMedicine RheumatoidArthritis Sarilumab Injecting) | Medicine.kif 5269-5269 | RheumatoidArthritis 是 对于 注射 的 disease 治愈 Sarilumab |
| (subclass Kevzara Sarilumab) | Medicine.kif 5271-5271 | Kevzara 是 Sarilumab 的 subclass |
| (termFormat EnglishLanguage Sarilumab "sarilumab") | Medicine.kif 5268-5268 |
|
|
|